(Q44631221)

4 December 2017

title

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum (English)

1 reference

4 December 2017

1 reference

11

Jeffrey H Kordower

1 reference

4 December 2017

6

Mark Tuszynski

1 reference

4 December 2017

4

Roy Bakay

1 reference

4 December 2017

Christopher D Herzog

1

1 reference

4 December 2017

Biplob Dass

2

1 reference

4 December 2017

Mehdi Gasmi

3

1 reference

4 December 2017

James E Stansell

5

1 reference

4 December 2017

Krystof Bankiewicz

7

1 reference

4 December 2017

Er-Yun Chen

8

1 reference

4 December 2017

Yaping Chu

9

1 reference

4 December 2017

Kathie Bishop

10

1 reference

4 December 2017

Raymond T Bartus

12

1 reference

4 December 2017

publication date

26 August 2008

1 reference

4 December 2017

1 reference

4 December 2017

volume

16

1 reference

4 December 2017

issue

10

1 reference

4 December 2017

page(s)

1737-1744

1 reference

Levodopa and the progression of Parkinson's disease

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Functional recovery in parkinsonian monkeys treated with GDNF

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

GDNF in treatment of Parkinson's disease: response to editorial

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Crossroads in GDNF therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Point source concentration of GDNF may explain failure of phase II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Convective delivery of glial cell line-derived neurotrophic factor in the human putamen

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Morphological effects of estrogen on cholinergic neurons in vitro involves activation of extracellular signal-regulated kinases

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways.

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Hyperplastic changes within the leptomeninges of the rat and monkey in response to chronic intracerebroventricular infusion of nerve growth factor

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

1 reference

https://api.crossref.org/works/10.1038%2FMT.2008.170

7 January 2021

Identifiers

DOI

10.1038/MT.2008.170

1 reference

4 December 2017

1 reference